AMCP partnership forum: Improving quality, value, and outcomes with patient-reported outcomes

Amanda Bain, David Barhoum, Kristen Binaso, Robyn Carson, Amber Coleman, Del Conyers, Deb Curry, Bahar Davidoff, Michele V. Davidson, Jessica Daw, Joseph Dicesare, Sarah Donelson, Amy Duhig, Seth Ginsberg, Douglas Goldstein, Hilary Hatch, John Kalada, Francis Kalush, Ross Maclean, Robert McburneyKellie Meyer, Michelle Mocarski, David Nilasena, Kyle Null, Lisa Opipari-Arrigan, Lou Sanquini, Rachel Clark Sisodia, Caroline Huber

Research output: Contribution to journalArticle

Abstract

Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions. While there have been significant strides by key health care stakeholders to further the development and use of PROs, there are a number of challenges limiting more widespread use. In light of these current challenges and the potential for PROs to improve health care quality and value, on October 19, 2017, the Academy of Managed Care Pharmacy convened a forum of key stakeholders representing patients, payers, providers, government, and pharmaceutical companies to discuss and identify solutions to the current challenges and barriers to further use of PROs. These discussions informed the development of participants' ideal future state in which PROs maximize the goals of all health care stakeholders and the actionable steps required to make the future state a reality. While stakeholders shared unique perspectives throughout the forum, they had consensus on 2 overarching issues: the importance of PROs in defining value, improving patient care, and implementing valuebased payment models and the need for strong organizational and operational systems to achieve optimal adoption and use. Participants identified several key challenges in PRO use and adoption: achieving a representative patient population, inclusion of PRO data in medication labels, the necessity for both standardized and customizable PROs, and operational and organizational barriers to collecting and analyzing PROs. To overcome these challenges, participants recommended that manufacturers should engage key stakeholders early and throughout the drug development process to ensure the most valid and representative PROs and patient populations will be included. To streamline the PRO collection process, participants suggested engaging pharmacists and other providers who may have more frequent interaction with patients. Participants also recommended that PRO collection and analysis should use common technology platforms, streamline components of clinician care to reduce workflow, and be integrated with claims data to provider payers a better understanding of patient health in real time. Finally, additional work should be done to develop patient-reported outcome measures that contain relevant measures for all healthcare stakeholders. While significant challenges remain in PRO development and adoption, participants agreed that greater use can only be achieved through collaboration and patientcentered care.

Original languageEnglish (US)
Pages (from-to)304-310
Number of pages7
JournalJournal of Managed Care and Specialty Pharmacy
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Health care
Health
Pharmaceutical Preparations
Delivery of Health Care
Bioelectric potentials
Labels
Patient Reported Outcome Measures
Quality of Health Care
Industry
Patient Advocacy
Patient-Centered Care
Workflow
Pharmacists
Population
Health Status

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy

Cite this

AMCP partnership forum : Improving quality, value, and outcomes with patient-reported outcomes. / Bain, Amanda; Barhoum, David; Binaso, Kristen; Carson, Robyn; Coleman, Amber; Conyers, Del; Curry, Deb; Davidoff, Bahar; Davidson, Michele V.; Daw, Jessica; Dicesare, Joseph; Donelson, Sarah; Duhig, Amy; Ginsberg, Seth; Goldstein, Douglas; Hatch, Hilary; Kalada, John; Kalush, Francis; Maclean, Ross; Mcburney, Robert; Meyer, Kellie; Mocarski, Michelle; Nilasena, David; Null, Kyle; Opipari-Arrigan, Lisa; Sanquini, Lou; Sisodia, Rachel Clark; Huber, Caroline.

In: Journal of Managed Care and Specialty Pharmacy, Vol. 24, No. 3, 01.03.2018, p. 304-310.

Research output: Contribution to journalArticle

Bain, A, Barhoum, D, Binaso, K, Carson, R, Coleman, A, Conyers, D, Curry, D, Davidoff, B, Davidson, MV, Daw, J, Dicesare, J, Donelson, S, Duhig, A, Ginsberg, S, Goldstein, D, Hatch, H, Kalada, J, Kalush, F, Maclean, R, Mcburney, R, Meyer, K, Mocarski, M, Nilasena, D, Null, K, Opipari-Arrigan, L, Sanquini, L, Sisodia, RC & Huber, C 2018, 'AMCP partnership forum: Improving quality, value, and outcomes with patient-reported outcomes', Journal of Managed Care and Specialty Pharmacy, vol. 24, no. 3, pp. 304-310. https://doi.org/10.18553/jmcp.2018.17491
Bain, Amanda ; Barhoum, David ; Binaso, Kristen ; Carson, Robyn ; Coleman, Amber ; Conyers, Del ; Curry, Deb ; Davidoff, Bahar ; Davidson, Michele V. ; Daw, Jessica ; Dicesare, Joseph ; Donelson, Sarah ; Duhig, Amy ; Ginsberg, Seth ; Goldstein, Douglas ; Hatch, Hilary ; Kalada, John ; Kalush, Francis ; Maclean, Ross ; Mcburney, Robert ; Meyer, Kellie ; Mocarski, Michelle ; Nilasena, David ; Null, Kyle ; Opipari-Arrigan, Lisa ; Sanquini, Lou ; Sisodia, Rachel Clark ; Huber, Caroline. / AMCP partnership forum : Improving quality, value, and outcomes with patient-reported outcomes. In: Journal of Managed Care and Specialty Pharmacy. 2018 ; Vol. 24, No. 3. pp. 304-310.
@article{8b816ac6cfa24a5c8a119059fa98b6d1,
title = "AMCP partnership forum: Improving quality, value, and outcomes with patient-reported outcomes",
abstract = "Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions. While there have been significant strides by key health care stakeholders to further the development and use of PROs, there are a number of challenges limiting more widespread use. In light of these current challenges and the potential for PROs to improve health care quality and value, on October 19, 2017, the Academy of Managed Care Pharmacy convened a forum of key stakeholders representing patients, payers, providers, government, and pharmaceutical companies to discuss and identify solutions to the current challenges and barriers to further use of PROs. These discussions informed the development of participants' ideal future state in which PROs maximize the goals of all health care stakeholders and the actionable steps required to make the future state a reality. While stakeholders shared unique perspectives throughout the forum, they had consensus on 2 overarching issues: the importance of PROs in defining value, improving patient care, and implementing valuebased payment models and the need for strong organizational and operational systems to achieve optimal adoption and use. Participants identified several key challenges in PRO use and adoption: achieving a representative patient population, inclusion of PRO data in medication labels, the necessity for both standardized and customizable PROs, and operational and organizational barriers to collecting and analyzing PROs. To overcome these challenges, participants recommended that manufacturers should engage key stakeholders early and throughout the drug development process to ensure the most valid and representative PROs and patient populations will be included. To streamline the PRO collection process, participants suggested engaging pharmacists and other providers who may have more frequent interaction with patients. Participants also recommended that PRO collection and analysis should use common technology platforms, streamline components of clinician care to reduce workflow, and be integrated with claims data to provider payers a better understanding of patient health in real time. Finally, additional work should be done to develop patient-reported outcome measures that contain relevant measures for all healthcare stakeholders. While significant challenges remain in PRO development and adoption, participants agreed that greater use can only be achieved through collaboration and patientcentered care.",
author = "Amanda Bain and David Barhoum and Kristen Binaso and Robyn Carson and Amber Coleman and Del Conyers and Deb Curry and Bahar Davidoff and Davidson, {Michele V.} and Jessica Daw and Joseph Dicesare and Sarah Donelson and Amy Duhig and Seth Ginsberg and Douglas Goldstein and Hilary Hatch and John Kalada and Francis Kalush and Ross Maclean and Robert Mcburney and Kellie Meyer and Michelle Mocarski and David Nilasena and Kyle Null and Lisa Opipari-Arrigan and Lou Sanquini and Sisodia, {Rachel Clark} and Caroline Huber",
year = "2018",
month = "3",
day = "1",
doi = "10.18553/jmcp.2018.17491",
language = "English (US)",
volume = "24",
pages = "304--310",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "3",

}

TY - JOUR

T1 - AMCP partnership forum

T2 - Improving quality, value, and outcomes with patient-reported outcomes

AU - Bain, Amanda

AU - Barhoum, David

AU - Binaso, Kristen

AU - Carson, Robyn

AU - Coleman, Amber

AU - Conyers, Del

AU - Curry, Deb

AU - Davidoff, Bahar

AU - Davidson, Michele V.

AU - Daw, Jessica

AU - Dicesare, Joseph

AU - Donelson, Sarah

AU - Duhig, Amy

AU - Ginsberg, Seth

AU - Goldstein, Douglas

AU - Hatch, Hilary

AU - Kalada, John

AU - Kalush, Francis

AU - Maclean, Ross

AU - Mcburney, Robert

AU - Meyer, Kellie

AU - Mocarski, Michelle

AU - Nilasena, David

AU - Null, Kyle

AU - Opipari-Arrigan, Lisa

AU - Sanquini, Lou

AU - Sisodia, Rachel Clark

AU - Huber, Caroline

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions. While there have been significant strides by key health care stakeholders to further the development and use of PROs, there are a number of challenges limiting more widespread use. In light of these current challenges and the potential for PROs to improve health care quality and value, on October 19, 2017, the Academy of Managed Care Pharmacy convened a forum of key stakeholders representing patients, payers, providers, government, and pharmaceutical companies to discuss and identify solutions to the current challenges and barriers to further use of PROs. These discussions informed the development of participants' ideal future state in which PROs maximize the goals of all health care stakeholders and the actionable steps required to make the future state a reality. While stakeholders shared unique perspectives throughout the forum, they had consensus on 2 overarching issues: the importance of PROs in defining value, improving patient care, and implementing valuebased payment models and the need for strong organizational and operational systems to achieve optimal adoption and use. Participants identified several key challenges in PRO use and adoption: achieving a representative patient population, inclusion of PRO data in medication labels, the necessity for both standardized and customizable PROs, and operational and organizational barriers to collecting and analyzing PROs. To overcome these challenges, participants recommended that manufacturers should engage key stakeholders early and throughout the drug development process to ensure the most valid and representative PROs and patient populations will be included. To streamline the PRO collection process, participants suggested engaging pharmacists and other providers who may have more frequent interaction with patients. Participants also recommended that PRO collection and analysis should use common technology platforms, streamline components of clinician care to reduce workflow, and be integrated with claims data to provider payers a better understanding of patient health in real time. Finally, additional work should be done to develop patient-reported outcome measures that contain relevant measures for all healthcare stakeholders. While significant challenges remain in PRO development and adoption, participants agreed that greater use can only be achieved through collaboration and patientcentered care.

AB - Patient-reported outcomes (PROs), which provide a direct measure of a patient's health status or treatment preferences, represent a key component of the shift toward patient-centered health care. PROs can measure the state of a patient's disease-specific and overall health throughout the care continuum, enabling them to have a variety of uses for key health care stakeholders. Currently, PROs are used in drug development, aligning patient and clinician goals in care, quality-of-care measures, and coverage and reimbursement decisions. While there have been significant strides by key health care stakeholders to further the development and use of PROs, there are a number of challenges limiting more widespread use. In light of these current challenges and the potential for PROs to improve health care quality and value, on October 19, 2017, the Academy of Managed Care Pharmacy convened a forum of key stakeholders representing patients, payers, providers, government, and pharmaceutical companies to discuss and identify solutions to the current challenges and barriers to further use of PROs. These discussions informed the development of participants' ideal future state in which PROs maximize the goals of all health care stakeholders and the actionable steps required to make the future state a reality. While stakeholders shared unique perspectives throughout the forum, they had consensus on 2 overarching issues: the importance of PROs in defining value, improving patient care, and implementing valuebased payment models and the need for strong organizational and operational systems to achieve optimal adoption and use. Participants identified several key challenges in PRO use and adoption: achieving a representative patient population, inclusion of PRO data in medication labels, the necessity for both standardized and customizable PROs, and operational and organizational barriers to collecting and analyzing PROs. To overcome these challenges, participants recommended that manufacturers should engage key stakeholders early and throughout the drug development process to ensure the most valid and representative PROs and patient populations will be included. To streamline the PRO collection process, participants suggested engaging pharmacists and other providers who may have more frequent interaction with patients. Participants also recommended that PRO collection and analysis should use common technology platforms, streamline components of clinician care to reduce workflow, and be integrated with claims data to provider payers a better understanding of patient health in real time. Finally, additional work should be done to develop patient-reported outcome measures that contain relevant measures for all healthcare stakeholders. While significant challenges remain in PRO development and adoption, participants agreed that greater use can only be achieved through collaboration and patientcentered care.

UR - http://www.scopus.com/inward/record.url?scp=85042563329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042563329&partnerID=8YFLogxK

U2 - 10.18553/jmcp.2018.17491

DO - 10.18553/jmcp.2018.17491

M3 - Article

C2 - 29460679

AN - SCOPUS:85042563329

VL - 24

SP - 304

EP - 310

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 3

ER -